

18 April 2022

Australia

## EQUITIES

### BRN-AU Not rated


Stock price as of 14/04/2022 A\$	0.91
GICS sector	Information Technology
Market cap	US\$m 1,157
Avg Value Traded (3m)	US\$m 29.2
12m high/low	A\$ 2.13/0.37
EV/Sales FY21	x 741.4
P/BV FY21	x 61.2

### Historical financials

YE Dec (US\$m)	2019A	2020A	2021A
Revenue	0.08	0.12	1.59
% growth	-92%	60%	1,215%
EBITDA	(10.0)	(10.2)	(18.9)
% growth	30%	-2%	-86%
EPS (US\$)	(0.01)	(0.02)	(0.01)
% growth	42%	-84%	30%
EBIT Margin	-13,219%	-8,443%	-1,191%

Source: Company data, FactSet, March 2022

### Historical business risk/reward\*



\*Relative to the market.  
Source: Macquarie Research, March 2022

### Style

Thematic
Growth
Value
Event

Source: Macquarie Research, March 2022

The subject Company discussed in this report is not under Macquarie Research's coverage. This report is not an initiation of coverage on the Company and does not intend to provide any rating or recommendation on the Company.

## MacVisit: Brainchip Inc

### Key points

- ▶ BRN is a pure-play AI company, producing a neuromorphic processor called Akida.
- ▶ Akida has utility across consumer and industrial applications, including autonomous vehicles, IoT devices, medical diagnosis.
- ▶ Neuromorphic chip market is still nascent in a commercial sense, there is high competition & new technology risk from major players (e.g Intel & IBM).

BRN is a semiconductor company that designs neuromorphic chips. BRN's AKD1000 relies on spiking neural networks (SNN) which enables high performance, real-time inference at ultra-low power. This is significantly less than the traditional AI chips relying on convolutional neural network (CNN) technology. BRN transitioned from R&D to commercialisation in H2 2021. BRN states it is the world's first commercial producer of neuromorphic chips.

### Advantages of the Akida chip

- **Independence from cloud:** Akida manages AI tasks at the Edge of the network instead of sending data to the cloud. Without needing an ongoing internet connection, Akida provides reduced system latency and faster response times.
- **One shot learning:** Reduces resources required to train models due to efficiency in accommodating new data inputs. Learns from very small set of samples and expands knowledge as more data is absorbed.
- **Low power consumption:** Uses 100 microwatts to a few hundred milliwatts of power depending on the workload. It generates minimal heat from consuming low power, so the chip should outlive the product it has been installed into.
- **On-chip fast learning and convolution:** Traditional software-based neural networks (e.g CNN) can be efficiently run on BRN's SNN by leveraging TensorFlow for industry standard neural network development. In April 2021, BRN introduced MetaTF as a versatile ML framework which allows people working in the CNN space to easily switch to neuromorphic computing without having to learn a new language.
- **Small and lightweight:** 28nm chip can be designed into wearable devices and flying machines (e.g drones, aircraft, spacecraft).

### Financials and risks

- FY21 revenue of US\$1.59M was a significant increase from US\$120,829 in FY20, but still loss-making on EBITDA level.
- Risks: IP, Reliance on key personnel, competition and new technologies, future funding requirements

### Akida has a broad range of applications with low power use



Source: BrainChip, Tech Brief, May 2020

## Ownership

Substantial shareholders in BRN include:

- **Peter Van Der Made (9.35%)**: Co-founder & CTO.
- **Anil Shamrao Mankar (5.87%)**: Co-founder & CDO.
- **Louis Dinardo (0.69%)**: Former CEO.
- **Steven Liebeskind (0.68%)**: Former Non-Executive Director.
- **LDA Capital (0.58%)**: US investment group, provides BRN with equity financing via a put option agreement.
- **Adam Osseiran (0.54%)**: Former Chair of the Scientific Advisory Board and former Non-Executive Director.
- **Rebecca Osseiran Moisson (0.40%)**: Wife of Adam Osseiran.

## Balance sheet data and refinancing (As of Dec 2021)

- Net cash outflow of US\$14.2M from operations in FY21.
- Net loss after income tax in FY21 of US\$21.0M, includes non-cash losses of US\$1.4M from fair valuation of LDA Capital financial liabilities, recognised from put option premium and agreed pricing mechanism.

## Directors' background

- **Sean Hehir (CEO & Executive Director)**: Joined in November 2021, a seasoned technology executive and board member of Silicon Valley Executive Network. Responsible for driving explosive revenue growth for HP, Compaq and Fusion-io.
- **Peter van der Made (CTO & Executive Director)**: Co-founder of BrainChip. Previously CTO, founder and Chief Scientist of vCIS Technology, later Chief Scientist when acquired by Internet Security Systems and IBM. Also founded PolyGraphics Systems.
- **Antonio Viana**: On the board of Arteris, a leading provider of NoC interconnect. Previously Executive Chairman at QuantalRF, former ARM President and EVP of Commercial and Global Development.
- **Geoffrey Carrick**: On the board of Global Study Partners and VCF Capital Partners. Previously Head of Equity Capital Markets at CBA, Director of Equity Capital Markets at Macquarie Group and Head of Finance of Shaw & Partners.
- **Pia Turcinov**: Manages a portfolio career with qualifications in business management and law.

**Fig 1 Board has average tenure of ~1.7 years**

Title	Name	Gender	Tenure (years)
Exec Director, Co-founder & CTO	Peter van der Made	M	6.5
Exec Director & CEO	Sean Hehir	M	0.3
Independent Non-Exec Director	Pia Turcinov	F	0.3
Independent Non-Exec Director	Geoffrey Carrick	M	1.3
Independent Non-Exec Chair	Antonio J Vianna	M	0.1
<b>Independence: 60%</b>		<b>Female (%): 20%</b>	<b>Average: 1.7</b>

Source: Company data, April 2022

## History and corporate governance

- Founded in 2013 by Peter Van der Made & Anil Shamrao Mankar, BrainChip Inc was acquired by Aziana Limited, a former mining company, and joined the ASX via a reverse listing in 2015.
- Aziana Limited merged with BrainChip Inc, divesting its existing mineral assets and the two were reinstated on the ASX as one entity BrainChip Holdings in September 2015.
- BRN is incorporated and domiciled in Australia. Apart from trading on ASX, BRN also trades under BCHPY (ADR) and BRCHF on the OTCQX.
- Employs a Scientific Advisory Board (SAB) consisting of three cognitive scientists and industry experts, including Nobel Prize Laureate Professor Barry J. Marshall, who joined in July 2020.
- In 2016, BRN acquired SpikeNet, a French company focusing on computer vision systems.

## Latest results highlights (4QFY21, Dec year-end)

- Finished quarter with US\$19.4M in cash. Increase of 1% YoY but decrease of 19% QoQ.
- Net operating cash outflows of US\$3.4M lower by 15% QoQ, with 83% increase in receipts from customers at US\$1.1M (US\$0.1M in Q3-21).

## Management background

- **Kenneth W. Scarince (CFO)**: Joined in 2019. Previously held senior management positions as Finance Director of Midwest Connect, Controller of Virgin Galactic, VP and Controller of Virgin America, VP Finance of Chicago Express Airlines.
- **Anil Shamrao Mankar (CDO)**: Co-founder of BrainChip, previously CDO for Conexant Systems LLC, VP Business Development at T2M and Senior VP-VLSI Engineering at Mindspeed Technologies.
- **Jerome Nadel (CMO)**: Joined in January 2022 from Rambus, a NASDAQ-listed semiconductor technology company. Previously held senior positions at Sagem, Thales, wireless and IoT solutions provider Option NV, Unisys and IBM. Board member of Silicon Valley Executive Network and President of Silicon Valley chapter of CMO club, a global community of marketing executives.

## What is Neuromorphic computing (aka Cognitive computing)

Neuromorphic computing hardwires AI and ML algorithms into an integrated circuit (printed circuit board) that closely reproduces the behaviour of the human brain. In devices with these types of circuits, each function is allowed as much time needed to complete its task. To allow for greater complexity and use less energy, all these functions work asynchronously and in parallel — like how neuroscientists believe the brain operates. The neurons of a neuromorphic computer work in parallel with each other, each doing what it needs to do to complete a task. They communicate via bursts of electric current, known as spikes.

**Spiking neural network (SNN)**: Instead of manipulating signals, the chip sends spikes along to activate synapses. Connections are asynchronous and highly timed-based. Neuromorphic cores containing many neurons are interlinked and receive spikes from elsewhere in the network. When received spikes accumulate for a certain period and reach a set threshold, the core will fire off its own spikes to its connected neurons. Preceding spikes reinforce each other and the neuron connections while spikes that follow will inhibit the connection, declining the connectivity until all activities are halted.

**Vs. modern conventional computer:** Asynchronous systems' roots go back to the earliest versions of the modern computer. The blueprint of the modern computer ("Von Neumann" machine) from the 1940s explains that asynchronous computation is advantageous. Many early machines were built this way, but computer architecture soon grew in complexity and included a lot more wires. Ensuring that a signal was sent and received correctly within the machine got trickier. An internal timekeeper was needed to make sure things ran properly, and synchronous circuits became the preferred platform.

### Competition

BRN states it has a competitive advantage over rivals in the commercialisation process as other neuromorphic chips are still in the R&D stage.

#### IBM TrueNorth

- Produced in 2014, a single processor consists of 5.4 billion transistors, 1 million neurons, 256 million synapses using 4,096 cores. Although it only uses milliwatts of power, each synapse needs to be programmed, which restricts the chip's learning capabilities in real-time. Does not have backward compatibility with previous technology (e.g C++ compilers) and has vendor lock-in risks. ML workflow requires learning Corelet.

#### Intel Loihi

- Introduced Loihi in January 2018 and its successor Loihi 2 in 2021, which provides 10x faster processing, 15x resource density and improved energy efficiency with a 7nm chip. Loihi 2 consists of 1 million neurons and 120 million synapses but lacks on-chip convolution and requires learning NEF for ML workflow. In 2019, Intel said they're 5 years away from commercialisation.

#### Google Coral TPU

- Introduced in 2019, Google Coral TPU is a ML application-specific integrated circuit (ASIC) designed to run AI at the edge. Provides high performance ML inferencing for low-power devices but only supports TensorFlow Lite. An individual Edge TPU performs 4 trillion (fixed-point) operations per second and consumes 2-5W of power.

#### DLAs (e.g Nvidia)


- Launched in 2017, Nvidia produced an open-source hardware neural network AI accelerator written in Verilog. It is configurable and scalable to meet a range of architecture needs. However, as an accelerator, any process must be scheduled and arbitered by an outside entity (e.g CPU). Available for product development as a part of Nvidia's Jetson Xavier NX.

**Fig 2 Competitive Space**

	Micro to MW Power Use	Standard ML Workflow	Standalone Possible (No CPU)	On-Chip Convolution
BrainChip Akida™ AKD1000	✓	✓	✓	✓
IBM TrueNorth	✓	Learn Corelet	✗	✗
Intel Loihi	✓	Learn NEF	✓	✗
Google Coral TPU	2-5W	✓	✗	✗
Deep Learning Accelerator (e.g Nvidia)	✗	✓	✗	✗


Source: BrainChip, BrainChip Introduction presentation, April 2022

**Fig 3 BRN operational highlights**



Source: Company data, April 2022

Estimates from various sources suggest edge computing will see a CAGR of between 19-49% over the coming 5-10 years (consensus average of 33% CAGR).

**Fig 4 Edge based devices requiring AI 2021e breakdown**

Source: BrainChip, Share Café Podcast presentation, June 2021

**Fig 6 BRN market traction**


Source: BrainChip Investor presentation, April 2022

**The growth proposition**


- **Strong demand for AI enabled IoT and edge devices**
- **Independence from cloud:** Akida's capabilities are suited to address the sustainability concerns raised by extreme power consumption and emissions from data centres, allowing a shift from traditional cloud data centres to processing on the device. Akida is ~97% more energy efficient compared to processing the same task at a data centre.
- **International growth:** New sales partnerships with technology solutions provider SalesLink and high-tech distributor Eastronics to expand Akida's commercial reach in Europe and Israel.
- **Future products:** BRN intends to evolve the Akida technology overtime. Chips currently in development include AKD2000, AKD3000 and the AKD500.

**The business model**

- **Chips and board sales:** Revenue from sales of Akida chips manufactured by third parties (i.e TSMC in Taiwan). PCIe Boards and Akida Development Kits (ARM-based Raspberry Pi & x86 Shuttle PC) are also available for order on their website.
- **IP licensing fees:** From single product to multi-product use, customers can use the Akida IP by purchasing IP licenses.
- **Non-recurring engineering (NRE):** One-off fees related to adapting Akida technology to specific integration needs.
- **Royalties:** Recurring royalties from each product sold that includes Akida IP by customers.

**Fig 5 Edge based devices 21-25e growth CAGR**

Source: BrainChip, Share Café Podcast presentation, June 2021

**Fig 7 Edge based devices requiring AI by 2025**

Source: BrainChip, Share Café Podcast presentation, June 2021

**The value proposition**

- **Early Access Program (EAP):** BRN receives market validation for Akida technology by signing multiple agreements, including with Ford Motor Company, Valeo and NASA. In January 2022, BRN announced that Information Systems Laboratories is developing an AI-based radar solution for the Air Force Research Laboratory based on Akida.
- **Easy adoption:** BRN's MetaTF software automates conversion from traditional networks into immediately usable and efficient spiking networks.

**The main risks**

- **IP risk:** Current portfolio has 8 US and 1 Chinese granted patent, but BRN should continue expanding international patent filings to maintain global competitive advantage. They have 21 pending applications in the US, Europe, Canada, Japan, Korea, Australia, Mexico, Brazil and Israel.
- **Reliance on key personnel:** If one or more key management personnel (BoD, CTO, CDO, CFO, sales VP) leave, it could weaken company management and strategy.
- **Competition and new technologies:** Some existing and/or potential competitors (e.g Intel, IBM) are more well-resourced than BRN which could risk future growth and development.
- **Future funding requirements:** Operations are largely loss-making to date, so BRN should secure additional funding to support development activities. Option agreement with LDA Capital allows BRN to access A\$65M funding when necessary until December 2023.

**Strengths**

- **Crossed threshold from R&D into commercialisation:** BRN evolved its operations to become the world's first and only commercial producer of neuromorphic AI chips in FY21.
- **Strong partnerships:** BRN has IP licensing agreements with Japan-based ASIC leader MegaChips and global semiconductor manufacturer Renesas.
- **Board composition:** Seasoned and highly qualified management team. Short average tenure of board members at 1.7 years could bring new strategic direction for BRN.

**Opportunities**

- **Large and fast-growing addressable market:** Akida architecture is flexible to address requirements for the increasing number of IoT and edge devices in consumer and industrial applications (e.g automotive, healthcare).
- **Expansion outside of North America:** North America is BRN's primary target market but through IP partners Renesas and MegaChips, BRN looks to enter the Japanese market and access the consumer electronics industry.

**Weaknesses**

- **Volatile share price:** ASX has conducted both an aware and price query for BRN in October 2021 and January 2022.
- **Cash burn:** Net operating cash flows in FY21 were US\$14.2M and are expected to grow for FY22 from increased Akida production.
- **Market uncertainty:** SNN technologies are at an early stage so there isn't a clear dominant technology in the market.

**Threats**

- **Competition:** Intel and IBM are bigger companies with more resources to potentially develop neuromorphic chips with higher performance and utility, which could render Akida obsolete.
- **Share overhang:** LDA Capital can sell the shares it owns in BRN (other than collateral shares) on the market at any time which would create sudden adverse share price movements.
- **Low adoption rate of Akida:** Customers' unfamiliarity with neuromorphic chips inhibits BRN's foray into foreign markets.

**Fig 8 BrainChip Financial Summary**

BrainChip (BRN)						Market Price: A\$1.00					
Interim		1H20	2H20	1H21	2H21	Full year		FY18	FY19	FY20	FY21
Revenue	US\$m	0.0	0.1	0.8	0.8	Revenue	US\$m	0.9	0.1	0.1	1.6
Cost of revenue	US\$m	-	(0.0)	(0.1)	(0.1)	Cost of revenue	US\$m	-	-	(0.0)	(0.3)
Gross profit	US\$m	0.0	0.1	0.6	0.7	Gross Profit	US\$m	0.9	0.1	0.1	1.3
Other Income	US\$m	-	-	0.4	-	Other Income	US\$m	-	-	-	0.4
OPEX, net (incl. D&A)	US\$m	(6.2)	(5.0)	(9.5)	(11.8)	OPEX, net (incl. D&A)	US\$m	(17.6)	(11.0)	(11.2)	(21.2)
Operating loss	US\$m	(6.2)	(5.0)	(8.4)	(11.1)	Operating loss	US\$m	(16.7)	(10.9)	(11.2)	(19.5)
EBITDA	US\$m	(5.9)	(4.4)	(9.1)	(9.8)	EBITDA	US\$m	(14.4)	(10.0)	(10.2)	(18.9)
Total other income/(expense)	US\$m	(0.7)	(15.0)	(0.7)	(0.6)	Total other income/(expense)	US\$m	0.1	(0.4)	(15.7)	(1.3)
Loss before income taxes	US\$m	(6.9)	(20.0)	(9.1)	(11.7)	Loss before income taxes	US\$m	(16.5)	(11.3)	(26.8)	(20.8)
Tax (expense)/benefit	US\$m	-	-	(0.1)	(0.0)	Tax (expense)/benefit	US\$m	-	-	-	(0.2)
Net loss	US\$m	(6.9)	(20.0)	(9.3)	(11.7)	Net loss	US\$m	(16.5)	(11.3)	(26.8)	(21.0)
EPS/(LPS)	cps	(0.5)	(1.3)	(0.5)	(0.7)	EPS/(LPS)	cps	(1.6)	(1.0)	(1.8)	(1.2)
PER (reported)	x	nmf	nmf	nmf	nmf	PER (reported)	x	nmf	nmf	nmf	nmf
Profit and Loss Ratios		FY18	FY19	FY20	FY21	Cashflow Analysis		FY18	FY19	FY20	FY21
Revenue grow th	%	252%	(92%)	60%	1215%	EBITDA	US\$m	(14.4)	(10.0)	(10.2)	(18.9)
EBITDA grow th	%	(16%)	30%	(2%)	(86%)	Change in working capital	US\$m	7.2	1.0	0.2	4.8
EV/Sales	x	1386.3	17390.1	10876.8	827.4	Operating cash flows	US\$m	(7.2)	(9.0)	(10.0)	(14.2)
EV/EBIT	x	-78.9	-120.3	-117.7	-67.3	Capex	US\$m	(1.2)	(0.2)	(0.0)	(0.3)
Balance Sheet Ratios		FY18	FY19	FY20	FY21	Other	US\$m	-	-	-	-
Net Debt/(Net Cash)	US\$m	(7.3)	(6.7)	(15.5)	(19.2)	Investing cashflows	US\$m	(1.2)	(0.2)	(0.0)	(0.3)
Net Debt/Equity	x	(0.8)	(0.7)	(0.9)	(1.0)	Receipts from the issue of shares	US\$m	-	7.4	2.0	-
Net Debt/EBITDA	x	0.5	0.7	1.5	1.0	Receipts from the exercise of unlisted o	US\$m	-	-	3.4	10.2
Interest cover (EBIT)	x	-	(20.6)	(39.4)	(675.0)	Other	US\$m	(0.0)	1.8	16.1	4.5
FFPOWA	m	1,006.9	1,187.2	1,527.5	1,719.2	Financing cash flows	US\$m	(0.0)	9.2	21.5	14.7
						Net Cashflow	US\$m	(8.5)	0.1	11.4	0.3
KPIs		FY18	FY19	FY20	FY21	Balance Sheet		FY18	FY19	FY20	FY21
Product revenue	US\$m	0.108	0.010	0.030	0.196	Cash	US\$m	8	8	19	19
License revenue	US\$m	0.327	0.002	0.000	0.825	Receivables	US\$m	0	1	1	1
Development service revenue	US\$m	0.513	0.063	0.091	0.567	Financial asset	US\$m	-	-	1	-
Revenue from NA	US\$m	0.7	0.0	0.1	1.4	PP&E	US\$m	0	0	0	0
Revenue from Oceania	US\$m	-	-	-	0.0	Intangibles	US\$m	2	2	1	2
Revenue from EMEA	US\$m	0.2	0.1	0.0	0.2	Other	US\$m	0	0	0	1
						Total Assets	US\$m	10	11	23	24
						Payables	US\$m	1	0	1	1
						Deferred revenue	US\$m	-	-	0	1
						Debt	US\$m	0	1	4	0
						Defined benefit plan	US\$m	0	0	0	0
						Other	US\$m	0	0	1	2
						Total Liabilities	US\$m	1	2	6	5
Current price	A\$	1.00				Shareholders Funds	US\$m	9	9	17	19
Market cap	US\$m	1287				Other	US\$m	-	-	-	-
Enterprise value	US\$m	1314				Shareholder Equity	US\$m	9	9	17	19

Source: Company data, April 2022

**Important disclosures:**

<p><b>Recommendation definitions</b></p> <p><b>Macquarie – Asia and USA</b> Outperform – expected return &gt;10% Neutral – expected return from -10% to +10% Underperform – expected return &lt;-10%</p> <p><b>Macquarie – Australia/New Zealand</b> Outperform – expected return &gt;10% Neutral – expected return from 0% to 10% Underperform – expected return &lt;0%</p> <p>Note: expected return is reflective of a Medium Volatility stock and should be assumed to adjust proportionately with volatility risk</p>	<p><b>Volatility index definition*</b></p> <p>This is calculated from the volatility of historical price movements.</p> <p><b>Very high–highest risk</b> – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.</p> <p><b>High</b> – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.</p> <p><b>Medium</b> – stock should be expected to move up or down at least 30–40% in a year.</p> <p><b>Low–medium</b> – stock should be expected to move up or down at least 25–30% in a year.</p> <p><b>Low</b> – stock should be expected to move up or down at least 15–25% in a year. * Applicable to select stocks in Asia/Australia/NZ</p> <p><b>Recommendations</b> – 12 months <b>Note:</b> Quant recommendations may differ from Fundamental Analyst recommendations</p>	<p><b>Financial definitions</b></p> <p>All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives &amp; hedging, IFRS impairments &amp; IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends &amp; minority interests</p> <p><b>EPS</b> = adjusted net profit / efpowa* <b>ROA</b> = adjusted ebit / average total assets <b>ROA Banks/Insurance</b> = adjusted net profit /average total assets <b>ROE</b> = adjusted net profit / average shareholders funds <b>Gross cashflow</b> = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares</p> <p>All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).</p>																				
<p><b>Recommendation proportions – For quarter ending 31 Mar 2022</b></p> <table><tr><td></td><td><b>AU/NZ</b></td><td><b>Asia</b></td><td><b>USA</b></td><td></td></tr><tr><td>Outperform</td><td>63.27%</td><td>69.10%</td><td>79.79%</td><td>(for global coverage by Macquarie, 6.23% of stocks followed are investment banking clients)</td></tr><tr><td>Neutral</td><td>30.61%</td><td>20.65%</td><td>18.09%</td><td>(for global coverage by Macquarie, 3.33% of stocks followed are investment banking clients)</td></tr><tr><td>Underperform</td><td>6.12%</td><td>10.25%</td><td>2.13%</td><td>(for global coverage by Macquarie, 1.16% of stocks followed are investment banking clients)</td></tr></table>				<b>AU/NZ</b>	<b>Asia</b>	<b>USA</b>		Outperform	63.27%	69.10%	79.79%	(for global coverage by Macquarie, 6.23% of stocks followed are investment banking clients)	Neutral	30.61%	20.65%	18.09%	(for global coverage by Macquarie, 3.33% of stocks followed are investment banking clients)	Underperform	6.12%	10.25%	2.13%	(for global coverage by Macquarie, 1.16% of stocks followed are investment banking clients)
	<b>AU/NZ</b>	<b>Asia</b>	<b>USA</b>																			
Outperform	63.27%	69.10%	79.79%	(for global coverage by Macquarie, 6.23% of stocks followed are investment banking clients)																		
Neutral	30.61%	20.65%	18.09%	(for global coverage by Macquarie, 3.33% of stocks followed are investment banking clients)																		
Underperform	6.12%	10.25%	2.13%	(for global coverage by Macquarie, 1.16% of stocks followed are investment banking clients)																		

**Company-specific disclosures:**

Important disclosure information regarding the subject companies covered in this report is available publicly at [www.macquarie.com/research/disclosures](http://www.macquarie.com/research/disclosures).

The name "Macquarie" refers to Macquarie Group Limited and its worldwide affiliates and subsidiaries (the "Macquarie Group").

**Analyst certification:**

The views expressed in this report accurately reflect the personal views of the analyst(s) about the subject company or companies and its or their securities. We also certify that no part of the compensation of the analyst(s) was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst(s) responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Limited (ABN 94 122 169 279, AFSL No. 318062) ("MGL") total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

**General disclosure:** This research has been issued by Macquarie Securities (Australia) Limited ("MSAL") ABN 58 002 832 126, AFSL 238947, a Participant of the ASX and Chi-X Australia Pty Limited. MSAL is the provider of the general advice and takes responsibility for the provision of this research. Please refer to MSAL's Financial Services Guide (FSG) for more information at <https://www.macquarie.com.au/advisers/financial-services-guide.html>.

This research is distributed in Australia by Macquarie Equities Limited ABN 41 002 574 923 AFSL 237504 ("MEL") a Participant of the ASX. Apart from Macquarie Bank Limited ABN 46 008 583 542 ("MBL"), any MGL subsidiary noted in this research, is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Australia) and that subsidiary's obligations do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of that subsidiary, unless noted otherwise.

This research contains general advice and does not take account of your objectives, financial situation or needs. Before acting on this general advice, you should consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research has been prepared for the use of the clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient, you must not use or disclose this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. This research is based on information obtained from sources believed to be reliable, but the Macquarie Group does not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. The Macquarie Group accepts no liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. The Macquarie Group produces a variety of research products, recommendations contained in one type of research product may differ from recommendations contained in other types of research.

The Macquarie Group has established and implemented a conflicts policy at group level, which may be revised and updated from time to time, pursuant to regulatory requirements; which sets out how we must seek to identify and manage all material conflicts of interest. Staff involved with the preparation of research have regular interaction with companies they cover. Additionally, MGL does and seeks to do business with companies covered by research. There are robust information barriers in place to protect the independence of research's product. However, recipients of research should be aware of this potential conflict of interest. The Macquarie Group, its officers and employees may have conflicting roles in the financial products referred to in this research and, as such, may effect transactions which are not consistent with the recommendations (if any) in this research. The Macquarie Group may

receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case. The Macquarie Group's employees or officers may provide oral or written opinions to its clients which are contrary to the opinions expressed in this research.

Important disclosure information regarding the subject companies covered in this report is available at [www.macquarie.com/disclosures](http://www.macquarie.com/disclosures)

© Macquarie Group